'Ischemic events' presentation slideshows

Perioperative Aspirin & POISE-2

Perioperative Aspirin & POISE-2. Neal Gerstein, MD FASE Associate Professor, UNM Department of Anesthesiology Director, UNM Division of Cardiac Anesthesia. Disclosures. None. Objectives. Review risks of holding aspirin perioperatively.

1.01k views • 73 slides

Acute Myocardial Infarction

Acute Myocardial Infarction. Laura Kay M.D. EMS Medical Director. Worldwide Statistics. Each year: > 4 million patients are admitted with unstable angina and acute MI > 900,000 patients undergo PTCA with or without stent. Cumulative 6-month mortality from ischemic heart disease.

1.91k views • 66 slides

Institute of Vascular Diseases Clinical Center University of Sarajevo

ESC-ACCP-ACC Guidelines in atherothrombosis. Institute of Vascular Diseases Clinical Center University of Sarajevo. Klju?ni faktori razvoja aterotromboze.

717 views • 47 slides

Heparin manufacturing

887 views • 46 slides

Intracoronary Streptokinase after Primary PCI

Intracoronary Streptokinase after Primary PCI. Sezer M et al., NEJM May 3 rd 2007. Context: Reperfusion after MI. Rupture of atherosclerotic plaque -> sudden thrombotic coronary occlusion Studies 1960ies: nonselective intracoronary fibrinolysis can restore perfusion

520 views • 40 slides

Model of Memory

Model of Memory. RETRIEVAL. Turning now to Long-Term Memory. ATTENTION. Sensory Memory. Short-Term Memory. Long-Term Memory. Sensory Signals. REHEARSAL. Some Distinctions in LTM. Endel Tulving: There are two broad categories of information that are represented in LTM -

721 views • 37 slides

New Perspectives in the Management of Type 2 Diabetes

New Perspectives in the Management of Type 2 Diabetes. Herold Merisier, MD, FAAFP Voluntary Assistant Professor of Family Medicine Miller School of Medicine, University of Miami Plantation, FL. Disclosure. Speaker: Novartis Pharmaceuticals Speaker: Novo-Nordisk. Diabetes 2010.

573 views • 36 slides

318 views • 31 slides

????? ??????????

????? ??????????. ??? ????? ??????? ?????. ???? ????. ?? 39 ?+3 , ????? ????? , ???? ??? ??????? , ?????. ?????? ????? ????? , ??? ???? ????? ??????. ?????? : ?? ????? ?? ??? ?? ???? 18 ???? ????? ????? ???? 12 ?? ????? ??????. ????? ????? ??"? ???? ????? ??????????

611 views • 30 slides

Evaluation of a novel, rationally designed, low-molecular-weight heparin during elective PCI: Results of the Phase 2 EM

Evaluation of a novel, rationally designed, low-molecular-weight heparin during elective PCI: Results of the Phase 2 EMINENCE Trial. Sunil V. Rao MD for the EMINENCE Investigators. EMINENCE Trial: Disclosures. Presenter disclosures

506 views • 28 slides

John H. Alexander, MD, MHSc Duke Clinical Research Institute, Durham, NC, USA

Safety of the factor Xa inhibitor, apixaban, in combination with antiplatelet therapy after acute coronary syndromes: Results from the APPRAISE-1 dose guiding trial. John H. Alexander, MD, MHSc Duke Clinical Research Institute, Durham, NC, USA Lars Wallentin, MD, PhD

441 views • 21 slides

Apixaban with Antiplatelet Therapy After Acute Coronary Syndrome: Results of the APPRAISE-2 Trial

Apixaban with Antiplatelet Therapy After Acute Coronary Syndrome: Results of the APPRAISE-2 Trial. John H. Alexander, MD, MHS on behalf of the APPRAISE-2 Investigators. Sponsored by Bristol-Myers Squibb and Pfizer. Disclosures for John H. Alexander.

807 views • 20 slides

Drug Safety Oversight Board: Recent Activities

326 views • 17 slides

Atorvastatin Versus Revascularization Treatments (AVERT) Trial

AVERT Trial. Atorvastatin Versus Revascularization Treatments (AVERT) Trial. Presented at The American Heart Association Scientific Sessions 1998 Presented by Dr. Bertram Pitt. AVERT Trial: Background.

362 views • 17 slides

Freek W.A. Verheugt

The Antiplatelet Sub-study of RE-LY. Discussion. Freek W.A. Verheugt. Department of Cardiology, Onze Lieve Vrouwe Gasthuis . Amsterdam, The Netherlands. Disclosures for Freek W.A. Verheugt. Antiplatelet vs. No antiplatelet: Bleeding. Hemorrhagic Stroke. DE 110. Major Bleed. DE 150.

299 views • 15 slides

On behalf of the TRILOGY ACS Investigators

237 views • 11 slides

Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate?.

248 views • 11 slides

Bliden et al. JACC. 2007 Feb 13; 49 (6): 657-66.

Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate?.

225 views • 11 slides

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events. Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel and aspirin in reducing the risk of thrombotic events in patients with atherosclerotic disease. Reference

477 views • 9 slides

163 views • 7 slides